Data completeness
0/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DIUTENSEN-R is a fixed-dose combination tablet containing methyclothiazide (a thiazide diuretic) and reserpine (an antihypertensive agent) for oral administration. This combination targets hypertension through dual mechanisms: diuretic-induced sodium/fluid reduction and sympathetic nervous system inhibition. The product is positioned as a legacy antihypertensive combination therapy.
Pre-Launch
Pre-launch stage indicates early market entry with uncertain commercial trajectory; team size and resource allocation depend heavily on competitive positioning and approval timeline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DIUTENSEN-R at pre-launch stage offers exposure to market entry strategy, competitive positioning, and regulatory execution in a mature therapeutic area. Career value depends on successful differentiation and approval timeline; involvement early could build deep product knowledge but faces headwind of legacy mechanism in crowded market.
Brand ManagerCommercial Operations Manager
Worked on DIUTENSEN-R at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.